HepB-CpG Vaccine in People With HIV and Prior Nonresponse to HBV Vaccine

This study provides the end-of-study results on the durability of seroprotection response in a trial comparing 2- and 3-dose hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) vs 3-dose hepatitis B vaccine with an aluminum hydroxide adjuvant.